Suscribirse

Advances in pediatric asthma in 2012: Moving toward asthma prevention - 27/12/12

Doi : 10.1016/j.jaci.2012.11.009 
Stanley J. Szefler, MD
Divisions of Pediatric Clinical Pharmacology and Allergy and Immunology, Department of Pediatrics, National Jewish Health, and the Departments of Pediatrics and Pharmacology, University of Colorado School of Medicine, Denver, Colo 

Corresponding author: Stanley J. Szefler, MD, National Jewish Health, 1400 Jackson St, Rm J304 Molly Blank Building, Denver, CO 80206.

Abstract

Last year’s “Advances in pediatric asthma: moving forward” concluded the following: “Now is also the time to utilize information recorded in electronic medical records to develop innovative disease management plans that will track asthma over time and enable timely decisions on interventions in order to maintain control that can lead to disease remission and prevention.” This year’s summary will focus on recent advances in pediatric asthma on modifying disease activity, preventing asthma exacerbations, managing severe asthma, and risk factors for predicting and managing early asthma, as indicated in Journal of Allergy and Clinical Immunology publications in 2012. Recent reports continue to shed light on methods to improve asthma management through steps to assess disease activity, tools to standardize outcome measures in asthma, genetic markers that predict risk for asthma and appropriate treatment, and interventions that alter the early presentation of asthma to prevent progression. We are well on our way to creating a pathway around wellness in asthma care and also to use new tools to predict the risk for asthma and take steps to not only prevent asthma exacerbations but also to prevent the early manifestations of the disease and thus prevent its evolution to severe asthma.

El texto completo de este artículo está disponible en PDF.

Key words : Airway remodeling, asthma, asthma control, asthma exacerbations, asthma impairment, asthma risk, asthma severity, early intervention in asthma, biomarkers, environment, genetics, inhaled corticosteroids, leukotriene receptor antagonists, long-acting β-adrenergic agonists, omalizumab, personalized medicine, severe asthma, therapeutics, tiotropium

Abbreviations used : Feno, HRV, ICS, LABA, RSV, SNP, Treg, TSLP


Esquema


 Supported in part by Public Health Services research grants HL-64288, HL-51834, AI-90052, HL-75416, HL-87811, ES-18181, and HL-98075; Caring for Colorado Foundation; the Denver Post Charities, a McCormick Foundation; and the Colorado Cancer, Cardiovascular, and Pulmonary Disease Program. Supported in part by Colorado CTSA grant UL1 RR025780 from NCRR/NIH and UL1 TR000154 from NIH/NCATS.
 Disclosure of potential conflict of interest: S. J. Szefler has consultant arrangements with Merck, Genentech, Boehringer Ingelheim, and GlaxoSmithKline; has received grants from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has submitted a patent for the National Heart, Lung, and Blood Institute CARE network.


© 2012  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 131 - N° 1

P. 36-46 - janvier 2013 Regresar al número
Artículo precedente Artículo precedente
  • Anaphylaxis from ingestion of mites: Pancake anaphylaxis
  • Mario Sánchez-Borges, Raúl Suárez Chacón, Arnaldo Capriles-Hulett, Fernán Caballero-Fonseca, Enrique Fernández-Caldas
| Artículo siguiente Artículo siguiente
  • Advances in adult asthma diagnosis and treatment in 2012: Potential therapeutics and gene-environment interactions
  • Andrea J. Apter

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.